P16.09
Background: Identification of broadly neutralizing HIV-1 monoclonal antibodies (bnmAbs) can facilitate the development of an effective HIV-1/AIDS vaccine and aid for prevention and treatment of HIV-1 infection. A lot of bnmAbs against HIV-1 were isolated in the past three years, most of which were isolated based on their binding activities to HIV-1 wild type or engineered envelope glycoprotein (Env).
Methods: Here, we developed a novel methodology for isolating HIV-1 bnmAbs based on antibody neutralization activity by displaying full-length antibody libraries on target cell surface followed by sorting the cells by antibody neutralization ability.
Results: After several rounds of sorting, a panel of human mAbs has been isolated that can neutralize various isolates from different clades when displayed on the surface of mammalian cells. Several isolated antibodies have been converted into soluble version and characterized. Three mAbs can neutralize several Chinese circulating tier 3 viruses. These antibodies exhibited neutralizing profiles that are complimentary with that of b12. We are currently characterizing the epitopes recognized by this panel of antibodies.
Conclusions: Functional screening of HIV-1 bnmAbs may help elucidate the mechanisms of antibody-mediated protection against viral infection.
